IRIDEX Corporation 2. Çeyrek 2026 Kazanç Çağrısı Özeti

IRIDEX Corporation Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 19, 2026 at 3:21 AM GMT+3 3 min read

• IRIX -15.83%

Strategic Transformation and Operational Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Management characterized the second quarter as a financial inflection point, achieving positive cash flow following a two-year effort to transform the cost structure and strengthen working capital management.

• The company is currently executing a long-anticipated headquarters relocation, a move intended to optimize infrastructure and improve long-term operational efficiency.

• Glaucoma performance was driven by a 35% increase in Cyclo G6 probe volume, which management attributes to targeted physician engagement via MedScout and tailwinds from Medicare Local Coverage Determinations (LCDs).

• Retina revenue declines were attributed to temporary commercial transitions and regulatory factors internationally, rather than a fundamental shift in product demand.

• Gross margins were impacted by cost pressures and softer retina systems margins, though management expects the ongoing shift to third-party contract manufacturers to drive improvements in 2027.

• International glaucoma growth was bolstered by distributor stocking in Japan and Brazil ahead of planned business transitions and regulatory blackout periods.

Operational Outlook and Guidance Assumptions

• Full-year 2026 revenue guidance of $51 million to $53 million is reaffirmed, assuming a pro forma growth of 1% to 5% when excluding Middle East revenue.

• Management anticipates a temporary reduction in cash on hand through 2026 due to safety stock inventory builds required to navigate regulatory blackout periods during the headquarters move.

• Retina performance is expected to return to low-single-digit growth in the second half of 2026, supported by the American Academy of Ophthalmology meeting and annual promotional programs.

• The company expects PASCAL systems to secure European MDR approval in the first half of 2027, which is anticipated to unlock meaningful demand in the EMEA region.

• Working capital is projected to become a cash tailwind in 2027 as elevated inventory levels are worked down following the completion of manufacturing transitions.

Structural Transitions and Risk Factors

• The headquarters relocation requires a new registration process, necessitating global registration blackout periods that management is mitigating through proactive inventory builds.

• Ongoing conflict in the Middle East remains a persistent headwind, leading management to exclude the region's revenue from their formal guidance framework.

• Regulatory constraints and inventory digestion by distributors in China impacted retina sell-through during the quarter.

• Operating expenses decreased 5% year-over-year, primarily due to the successful transfer of administrative functions to lower-cost structures.

Q&A Session Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Retina growth expectations for the second half of 2026

• Management expects low-single-digit growth for retina in the second half, driven by international regulatory progress and seasonal U.S. promotional activities.

• Q4 is historically the company's largest quarter, and management expects this seasonal trend to persist in 2026.

Sustainability of record Cyclo G6 probe volumes

• While the 17.7 thousand units included some 'lumpy' stocking orders from Japan and Europe to cover blackout periods, underlying growth remained strong at over 15%.

• Management expects low-double-digit growth for glaucoma probes to continue through the second half of the year.

Recovery of Cyclo G6 system placement numbers

• The dip to 18 units was attributed to order timing in EMEA and competitive pressures in Germany.

• Management anticipates system sales will increase in the back half of the year, particularly in Q4, as they work through the UK registry and reimbursement processes.